NASH
FDA Approves Resmetirom, First Drug for MASH
The FDA granted accelerated approval to the first medication for the treatment of MASH, Rezdiffra.
MARCH 16, 2024
Aldafermin Shown to Reduce ELF Scores in Patients With MASH Cirrhosis
A trial evaluating aldafermin has found it effective and largely well tolerated in patients with compensated ...
FEBRUARY 20, 2024
NASH: An Interesting Space to Watch
Dr. Aimee Tharaldson, a keynote speaker at AMCP Nexus 2023, spoke with us about the pipeline for nonalcoholic ...
OCTOBER 24, 2023
Nonalcoholic Steatohepatitis: Treatment Options for High-Risk Patients
The management of NAFLD and NASH involves treatment of liver disease and its complications, control of risk ...
OCTOBER 20, 2022
NASH Dash: The Pipeline Race is on for New Agents
The year 2022 could see, for the first time, FDA-approved medications for nonalcoholic steatohepatitis (NASH). ...
JANUARY 7, 2022
